Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice TargetHot
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.